Hansoh Pharma Combination Extends Progression-Free Survival in Phase 3 Lung Cancer Study
Hansoh Pharma said dalmelitinib plus aumolertinib extended progression-free survival in a Phase 3 lung cancer study.
Hansoh Pharma said dalmelitinib plus aumolertinib extended progression-free survival in a Phase 3 lung cancer study.